AlphaStocks
4.2
Weak

Hims & Hers Health, Inc. (HIMS)

As of Sep 19, 2026, Hims & Hers Health, Inc. (HIMS) scores 4.2/10 on AlphaStocks' five-model composite, #133 of 168 Health Care stocks. At $28, HIMS trades 131% above its model fair value of $12.

Health Care / Health Care Services

S&P MidCap 400

$27.98

Below average on several measures. Research carefully.

Weak

Score based on 4 of 5 models — moderate confidence

Data as of Sep 19, 2026

#133out of 168 in Health Care

Is Hims & Hers Health, Inc. a Good Investment in 2026?

Hims & Hers Health, Inc. (HIMS) scores 4.2 out of 10 on AlphaStocks' composite model, earning a Weak rating. The Piotroski model is the most favorable, rating Hims & Hers Health, Inc. as Neutral. However, the Greenblatt Magic Formula model rates it Caution — Earnings yield 1.1% · ROC 7%. Hims & Hers Health, Inc. currently trades 131% above its estimated fair value of $12. Hims & Hers Health, Inc. ranks #133 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E56.3ROE18.8Market Cap6B

Estimated Fair Value

$12.12131% above

Trading above estimated fair value. P/e of 56x implies high growth expectations. eps growth of -7% may not justify the premium.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Neutral

4/9

Buffett

Caution

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Limited Data

Growth rate vs price (PEG)

Greenblatt

Caution

Earnings yield 1.1% · ROC 7%

Frequently Asked Questions

Is Hims & Hers Health, Inc. (HIMS) a good investment?
As of Sep 19, 2026, Hims & Hers Health, Inc. (HIMS) scores 4.2/10 on AlphaStocks' five-model composite, #133 of 168 Health Care stocks. At $28, HIMS trades 131% above its model fair value of $12. That score is below average, suggesting caution.
What is Hims & Hers Health, Inc.'s Piotroski F-Score?
Hims & Hers Health, Inc.'s Piotroski F-Score status is Neutral. The raw score is 4/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is HIMS overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $12, HIMS appears overvalued. The stock currently trades 131% above its estimated fair value. Trading above estimated fair value. P/e of 56x implies high growth expectations. eps growth of -7% may not justify the premium.
How does HIMS compare to other Health Care stocks?
Hims & Hers Health, Inc. ranks #133 out of 168 stocks in the Health Care sector, placing it in the top 79% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about HIMS?
AlphaStocks evaluates HIMS using five proven investment models. Piotroski: Neutral; Buffett: Caution; Graham: Caution; Greenblatt Magic Formula: Caution. These models are combined into a single composite score of 4.2/10.

Similar Stocks

DVAMDDGX

Compare HIMS with

DVA vs HIMSHIMS vs MDDGX vs HIMS

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer